OBJECTIVES: The Cue COVID-19 test is an at-home molecular nucleic acid amplification test (NAAT) that detects the RNA of SARS-CoV-2 using a nasal swab sample, with an accuracy rate of 98.9%. This study aims to understand how clinicians who treat immunocompromised (IC) patients view the Cue COVID-19 test, how the Cue COVID-19 test compares to other COVID-19 tests, and the types of IC patients who would benefit from access to Cue COVID-19 tests.

METHODS: Data for the study were collected using a modified Delphi panel methodology. Two sets of electronic surveys were administered in fall 2022 eliciting the opinions of expert panelists on the value of the Cue COVID-19 test, the IC patient population who should be regularly tested for COVID-19, and recommendations on when and how these patients may be tested. Consensus rules were defined a priori; consensus was defined as agreement by ≥ 75% of the panelists.

RESULTS: Expert opinions were anonymously collected from eight oncologists/ hematologists/ immunologists with extensive experience treating IC patients in the US. Consensus was achieved that the Cue COVID-19 test would provide value to all IC patients, and that they would benefit from access to this at-home test. Particularly, the panelists agreed that patients would benefit if they were symptomatic, exposed to COVID-19, undergoing chemotherapy, or have HIV with low CD4 count. Panelists recommended that patients should have access to between 1 and 6 Cue COVID-19 tests per month (average of 2.5 tests/month).

CONCLUSIONS: The study aims to understand the value of the Cue COVID-19 test for IC patients. Clinicians included on this panel agreed that the Cue COVID-19 test would provide value to IC patients, and that IC patients should have access to between 1 and 6 tests per month (average of 2.5 tests/month), for particular use when symptomatic, exposed to COVID-19, or while undergoing chemotherapy.